MedTrace Logo

Smoking Cessation Treatment for Head and Neck Cancer Patients

NCT00931021 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2013-07-15

No results posted yet for this study

Summary

This is a pilot research study examining the use of varenicline (Chantix) and the nicotine patch. The study is designed to find out whether one of these medications is more effective for smoking cessation with head and neck cancer patients. The study has three parts: 1) two intake sessions; 2) an 8-week treatment phase, and 3) a 3-month follow-up.

Conditions

  • Smoking Cessation

Interventions

DRUG

Varenicline (Chantix)

2 mg

DRUG

Nicotine Patch

21 mg

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Benjamin Toll, Ph.D. · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00931021 on ClinicalTrials.gov